Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.

Author: AgarwalPrasheen, ChakravartySoumya D, GottliebAlice B, HsiaElizabeth C, JiangYusang, KollmeierAlexa P, McInnesIain B, MeasePhilip J, RahmanProton, ShengShihong, SubramanianRamanand A, XuXie L, ZhouBei, ZhuangYanli, van der HeijdeDésirée

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase III DISCOVER-2 trial found that guselkumab provided sustained improvements across diverse manifestations of psoriatic arthritis (PsA) and maintained a favorable risk-benefit profile through week 52.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Guselkumab, a human monoclonal antibody specific to interleukin-23p19, demonstrated efficacy and safety versus placebo through week 24 of the phase III DISCOVER-2 trial in biologic-naive patients with psoriatic arthritis (PsA). Here we report 1-year DISCOVER-2 findings. METHODS: Adults w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291746/

データ提供：米国国立医学図書館（NLM）

Guselkumab: A Sustainable Oasis in the Desert of Psoriatic Arthritis Treatment

Psoriatic arthritis (PsA), a chronic inflammatory disease, is a formidable foe, akin to a relentless desert storm, relentlessly attacking the body's joints. This study investigates the long-term efficacy and safety of guselkumab, a human monoclonal antibody specifically targeting interleukin-23p19, offering a potential oasis of relief for patients navigating this challenging landscape.

The authors meticulously analyzed data from the DISCOVER-2 trial, a comprehensive study that spanned one year, exploring the effects of guselkumab in biologic-naive patients with PsA. Their findings demonstrate that guselkumab provided sustained improvements across diverse manifestations of PsA, offering a beacon of hope in the desert of treatment.

Guselkumab: A Beacon of Hope in the Desert of PsA Treatment

The study shows that guselkumab, like a well-placed oasis in the desert, provided significant and lasting relief for patients with PsA, reducing pain, inflammation, and joint damage. This is a testament to the power of targeted therapies and the potential for long-term management of this chronic disease.

Navigating the Desert of Chronic Illness: A Sustainable Path to Wellness

The study also emphasizes the importance of finding sustainable solutions for chronic illnesses, like ensuring a reliable water source in a desert environment. The sustained efficacy and favorable safety profile of guselkumab offer a promising path towards managing PsA, allowing patients to live healthier and more fulfilling lives.

Dr.Camel's Conclusion

This study offers a glimpse of hope for those facing the challenges of PsA. Guselkumab, with its targeted approach and lasting benefits, provides a valuable tool for managing this chronic disease. As we continue to journey through the desert of medical research, we must strive to develop innovative and sustainable solutions, creating a more equitable and hopeful future for all those seeking relief from chronic illnesses.

Date :
  1. Date Completed 2021-04-27
  2. Date Revised 2022-07-21
Further Info :

Pubmed ID

33043600

DOI: Digital Object Identifier

PMC9291746

Related Literature

Article Analysis
・Effects of guselkumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.